EGFR and lung carcinoma: The aim of this study was to reposition FDA-approved drugs as part of combination therapy to overcome acquired resistance to EGFR TKIs in lung cancer and to tamoxifen in breast cancer, targeting their common mechanisms underlying off-target acquired resistance.